HIV-1 capsid

Lenacapavir interferes with both early and late stages of HIV-1 replication, but is more effective against the early stages [2]. Lenacapavi (GS-6207) is a potent capsid inhibitor of HIV replication. Lenacapavi performs well in target cells (EC50=23 pM), full cycle assay (EC50=25 pM), and producer cells (EC50=439 PM).
In vitro, LEN showed potent antiviral activity against SHIV, as it did for HIV-1. In macaques, a single subcutaneous administration of LEN demonstrated dose proportional increases in and durability of drug plasma levels. [3]

A high-dose SHIV inoculum for the PrEP efficacy evaluation was identified via virus titration in untreated macaques. LEN-treated macaques were challenged with high-dose SHIV 7 weeks after drug administration, and the majority remained protected from infection, as confirmed by plasma PCR, cell-associated proviral DNA, and serology testing. Complete protection and superiority to the untreated group was observed among animals whose LEN plasma exposure exceeded its model-adjusted clinical efficacy target at the time of challenge. All infected animals had subprotective LEN concentrations and showed no emergent resistance. These data demonstrate effective SHIV prophylaxis in a stringent macaque model at clinically relevant LEN exposures and support the clinical evaluation of LEN for HIV PrEP in humans.[3]

MicroScale Thermophoresis Assays [1]
The binding affinities of CA with Pep-1 and PF74 were determined by measuring thermophoresis of fluorescently labeled CA-hexamers in the presence of increasing Pep-1 or PF74 concentrations. Peptide Pep-1 was synthesized in the Molecular Interaction Core and PF74 was purchased commercially. Fluorescent labeling of CA with Alexa Fluor 647 analog NT647 was performed according to the manufacturer’s instructions (MO-L004 Monolith Protein Labeling Kit). Briefly, 20 μM protein was incubated overnight with 3 M excess of dye at room temperature in a conjugation buffer provided with the labeling kit. The unreacted dye was removed by filtration through a gravity flow column provided with the kit. The elution fractions were collected in 2× MST buffer (40 mM MOPS, pH 7.2, 200 mM NaCl, and 0.2% pluronic F-127). Fluorescence intensity of each fraction was evaluated by MST, and fractions containing labeled protein were pooled. Protein concentration was determined by NanoDrop spectrophotometer. Aliquots were stored at −80°C until use. The reaction mixtures containing 200 nM labeled CA-hexamer and increasing concentrations of Pep-1 (1–2,000 nM) were loaded in the capillaries and the thermophoresis was monitored at 20% LED power, high MST power with 20 s MST-on time.

---

In vitro HIV-1 CA assembly assay.[2]
The in vitro assembly of HIV-1 CA protein in the presence and absence of small molecule library compounds (10 μM) or 2-fold serially diluted GS-6207 was monitored by measuring changes in sample absorbance over time at 350 nm. Final assembly reactions contained 20 μM CA, 2 M NaCl, 50 mM sodium phosphate pH 7.5, 0.005% Antifoam 204 (Sigma-Aldrich) and 1% DMSO. Sample absorbance values at 350 nm were monitored over time at 25°C in 96-well or 384-well plates using an M5 plate reader, corrected for absorbance values in the absence of CA or NaCl, and the data analyzed using SoftMax Pro 6.3.1 as previously described38.

---

GS-6207 binding assay.[2]
Surface plasmon resonance biosensor binding experiments were performed using the ProteOn XPR36 platform (CA hexamer and pentamer proteins) or the Biacore T100 platform (CA monomer and Gag proteins) as previously described21. Data were analyzed using ProteOn Manager 3.1.0 or Scrubber 2.0 and fit with a simple kinetic model with a term for mass transport added when necessary.

Cytotoxicity assays.[2]
For cytotoxicity assessment in MT-4 cells, PBMCs, primary human CD4+ T-cells and monocyte-derived macrophages, the protocol was identical to that of the respective antiviral assay, including assay duration, except that no virus was added to the plates. Protocols for cytotoxicity assessments in Huh-7, Gal-HepG2, Gal-PC-3 and MRC-5 cell lines, as well as in primary human hepatocytes, have been previously described37. The effect of test compounds on cell viability was measured using CellTiter-Glo. Data analysis was performed using GraphPad Prism 7.0 to calculate CC50 values.

---

GS-6207 resistance analysis.[2]
Dose-escalation selections for drug-resistant HIV-1 variants were performed in MT-2 cells infected with HIV-1HXB2D using twofold incremental increases in GS-6207 concentration as previously described31. The resistance profile of each emergent virus passage was then assessed in the 5-day cytoprotection antiviral MT-2 assay after titrating virus inoculums to normalize the m.o.i. across all samples. Viral breakthrough selections were conducted under conditions of fixed, constant drug concentrations over a period of 35 days in human PBMCs independently infected with six different HIV-1 isolates (BaL, 92US657, 91US0006, 7406, 7467 and 7576) as previously described21. GS-6207 was tested at fixed drug concentrations equal to 4-fold, 8-fold, and 16-fold its EC95 value of 0.23 nM (0.92 nM, 1.9 nM, and 3.7 nM GS-6207, respectively), using six replicate cell cultures per experimental condition. Viruses that emerged in the presence of GS-6207 were genotyped by population sequencing. Total RNA was isolated from mock- and GS-6207-selected virus-containing supernatants using the QiaAMP Viral RNA Mini Kit. A 986-bp fragment encoding HIV-1 capsid and the adjacent p2 spacer peptide was amplified by RT-PCR using the Qiagen OneStep RT-PCR Kit in combination with primers 5’-CAGTAGCAACCCTCTATTGTGTGC-3’ and 5’-CCTAGGGGCCCTGCAATTT-3’. RT-PCR products were sequenced by Elim Biopharmaceuticals. To identify codon changes, gene sequences from selected HIV-1 variants were aligned using DNA Sequencher 4.9 Software with that of the input virus and virus passaged in the absence of GS-6207. For samples containing > 1 codon change, PCR products were subcloned, DNA was isolated from individual bacterial colonies, and the CA gene was sequenced to assess the linkage of all observed substitutions.

Drug and formulation.[3]
\nLEN and the liquid chromatography–mass spectrometry internal standard GS-224337 were synthesized internally. and subjected to a standard quality control analysis. For antiviral assays, LEN was dissolved in DMSO to produce a 10 mM stock concentration and stored frozen at –0°C. For animal dosing studies, LEN was dissolved in vehicle (58.03% polyethylene glycol 300, 27.1% water, 6.78% ethanol, 6.61% poloxamer 188, 1.48% sodium hydroxide) at 300 mg/mL, stored at ambient temperature, and protected from light until dosing. The formulation contained additional excipients absent from the clinical formulation in order to tailor the pharmacokinetic profile in macaques.

---

\n\nAnimal studies.[3]
\nAll animals were housed at Bioqual Inc. For the in vivo SHIV stock titration study, 8 untreated outbred Indian-origin male rhesus macaques aged 3–5 years were challenged intrarectally per round for a total of 5 challenge rounds using increasing virus doses ranging from 0.625 to 100 TCID50, with the 100 TCID50 round performed twice for increased resolution (Supplemental Table 2). Plasma viral load was measured to confirm the infection status. For LEN pharmacokinetics and PrEP efficacy determination, 20 outbred Indian-origin male rhesus macaques aged 3–5 years were assigned to 5 study groups with an even weight distribution (Supplemental Table 2). On study week 0, 4 animals per group were administered LEN at 5, 10, 20, 50, or 75 mg/kg in the scapular region by subcutaneous injection. LEN was prepared as a 300 mg/mL stock solution, and no more than 2 mL solution was injected into a single subcutaneous site. Injection sites were monitored daily by veterinary staff for 2 weeks and then weekly through the end of study. On week 7, 11 animals were challenged by the intrarectal route with 1 mL RPMI containing 100 TCID50 SHIV-SF162P3. Whole blood was collected and processed into plasma and PBMCs as necessary for the assessment of routine hematology and clinical chemistry, viral load analysis, serology, and the bioanalysis of drug levels. Animals were considered protected if they remained SHIV negative by a plasma PCR assay and seronegative by enzyme immunoassay through week 10 after challenge.\n\nAnimals confirmed as SHIV positive in both the virus titration and the PrEP efficacy studies were placed on a daily subcutaneous ART regimen between weeks 4 and 10 after infection to prevent AIDS disease progression. The formulated ART cocktail contained tenofovir disoproxil fumarate (5.1 mg/mL), emtricitabine (40 mg/mL), and dolutegravir (2.5 mg/mL) and was administered subcutaneously once daily at 1 mL/kg.
\n\n\n\n

\n

View More

\n

\nBioanalysis of LEN in macaque plasma.[3]
\nRhesus plasma samples were stored frozen at –80°C and thawed, and a 50 μL aliquot of each was treated with 200 μL acetonitrile containing an internal standard. After precipitation of the protein component, a 100 μL aliquot of the supernatant was transferred to a clean 96-well plate and mixed with 200 μL water. A 10 μL aliquot of the above solution was then injected into a Q-Exactive high resolution mass spectrometer from Thermo Electron with electrospray ionization in positive mode. Quantification was performed using an accurate mass ([M+H]+) of 968.1508 for LEN and 756.3289 for the internal standard. The lower and upper limits of quantitation for LEN were 1 nM and 10,000 nM, respectively.

---

\n\nPlasma viral load assay.[3]
\nA QIAsymphony SP (Qiagen) automated sample preparation platform along with a Virus/Pathogen DSP midi kit and the cellfree500 protocol were used to extract viral RNA from 500 μL plasma. A reverse primer specific to the gag gene of SIVmac251 (5′-CACTAGGTGTCTCTGCACTATCTGTTTTG-3′) was annealed to the extracted RNA and then reverse transcribed into cDNA using SuperScript III Reverse Transcriptase along with RNAse Out (Thermo Fisher Scientific). The resulting cDNA was treated with RNase H (Thermo Fisher Scientific) and then added (2 replicates) to a custom 4× TaqMan Gene Expression Master Mix (Thermo Fisher Scientific) containing primers and a fluorescently labeled hydrolysis probe specific for the gag gene of SIVmac251 (forward primer 5′-GTCTGCGTCATCTGGTGCATTC-3′, reverse primer 5′-CACTAGGTGTCTCTGCACTATCTGTTTTG-3′, probe 5′-/56-FAM/CTTCCTCAGTGTGTTTCACTTTCTCTTCTGCG/3BHQ_1/-3′). The qPCR was then carried out on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific). Mean SIV gag RNA copies per reaction were interpolated using quantification cycle data and a serial dilution of a highly characterized custom RNA transcript containing a 730 bp sequence of the SIV gag gene. The assay limit of quantification is approximately 62 RNA copies per milliliter of sample.

---

\n\nELISA.[3]
\nRhesus serum samples from viremic study animals were tested for the presence of antibodies against HIV-1 by ELISA using the GS HIV-1/HIV-2 PLUS O EIA assay kit from Bio-Rad. Individual macaque sera (150 μL) mixed with 50 μL specimen diluent supplied in the kit were added to assay plates precoated with recombinant purified HIV-1 capsid (p24) protein and transmembrane glycoprotein (gp160) and incubated for 1 hour at room temperature. The plates were then washed 3 times with a sodium chloride and Tween 20–containing wash buffer from the kit and incubated for 1 hour with a HRP-conjugated antigen solution containing peptides mimicking various immunodominant epitopes of HIV-1 gp160 and p24 proteins. Wells with antibody against HIV-1 bound to the antigen coating the wells and to the peroxidase-conjugated antigens in the conjugate solution to form immobilized stable antigen-antibody-antigen complexes. The plates were washed 3 more times with the above wash buffer, developed with a working solution of tetramethylbenzidine, stopped by the addition of 1 N sulfuric acid, and analyzed at 450 nm using a Versamax microplate reader using the Softmax Pro 6.5.1 software. Samples with an OD450 nm absorbance value of more than 0.2 were considered positive.

---

\n\nIPDA.[3]
\nThe SHIV-adapted version of IPDA (SHIV-IPDA) was used to determine the number of intact SHIV proviruses. Total genomic DNA was extracted from unfractionated PBMCs using a QIAamp DNA Mini kit. DNA quality and quantity were evaluated by spectrophotometry and fluorometry, respectively, and SHIV-IPDA was then performed on the isolated DNA. In brief, SHIV-IPDA consists of a 3-component multiplex droplet-digital PCR (ddPCR) reaction. The first is a SHIV proviral discrimination reaction targeting two conserved, frequently deleted regions of the SHIV genome to determine the intact provirus count; the second is a 2-long terminal repeat (2-LTR) DNA circle reaction to determine 2-LTR circle counts; and the third is a copy reference/DNA-shearing reaction targeting ribonuclease P/MRP subunit P30 (RPP30) to determine assay input cell equivalents and the DNA shearing index. All ddPCR reactions were performed using a Bio-Rad QX200 AutoDG ddPCR system with Bio-Rad ddPCR supermix for probes with no dUTP. After DNA shearing index correction and subtraction of intact 2-LTR circles, the intact proviral frequencies were reported per million input cells. The endpoint ddPCR data were collected using Bio-Rad QuantaSoft version 1.7.4.0917.

---

\n\nPlasma virus genotypic analysis.[3]
\nTotal RNA was extracted from 50 μL plasma aliquots obtained from each viremic monkey using the MagMAX-96 Viral RNA Isolation Kit (Life Technologies) in conjunction with the Thermo Fisher Scientific KingFisher Flex automated extraction platform and eluted in 60 μL AVE buffer. The capsid coding area of gag in each sample was then individually amplified by RT-PCR using the SuperScript IV One-Step RT-PCR System (Life Technologies) and the Qiagen OneStep RT-PCR Kit according to the manufacturers’ recommended protocols. Amplification of the SHIV capsid coding region in each sample was performed using primers (SIV-CA-F [5′-CCAAAAACAAGTAGACCAACAG-3′] and SIV-CA-R [5′-TGCAAAAGGGATTGGCAC-3′]) and the products subjected to population-level bulk sequencing at Elim Biopharmaceuticals Inc. using the same primer set. To identify codon changes, capsid encoding sequences for each sample were aligned using DNA Sequencher Software (Gene Codes Corporation) with that of the parent challenge virus stock. A sequence alignment for major consensus HIV-1 subtype, HIV-2, and SHIV-SF162P3 capsid amino acid sequences was performed using BioEdit Sequence Alignment Editor version 7.2.6.\n

\n

\n\n

Absorption, Distribution and Excretion
Following subcutaneous injection, lenakapavir is slowly released but completely absorbed, with peak plasma concentrations occurring at 84 days post-administration. Absolute bioavailability after oral administration is low, ranging from approximately 6% to 10%. The time to peak concentration (Tmax) after oral administration is approximately 4 hours. The mean steady-state peak plasma concentration (Cmax) (%CV) after oral and subcutaneous administration is 97.2 (70.3) ng/mL. Based on population pharmacokinetic analysis, HIV-1-infected patients who had previously received extensive treatment had lenakapavir exposures (AUCtau, Cmax, and Ctrough) that were 29% to 84% higher than those who were not infected with HIV-1. The effect of a low-fat meal on drug absorption is negligible. Following a single intravenous injection of radiolabeled lenakapavir in healthy subjects, 76% of the total radioactivity was recovered in feces, and less than 1% was recovered in urine. The major components in plasma (69%) and feces (33%) are unmetabolized lenakapavir. The steady-state volume of distribution is 976 L in heavily treated HIV-1 infected patients. The clearance rate of lenakapavir in heavily treated HIV-1 infected patients is 3.62 L/h. Metabolism/Metabolites: Metabolism plays a minor role in the clearance of lenakapavir. It is metabolized via CYP3A4 and UGT1A1-mediated oxidation, N-dealkylation, hydrogenation, amide hydrolysis, glucuronidation, hexose conjugation, pentose conjugation, and glutathione conjugation. The metabolites of lenakapavir have not been fully elucidated. No single circulating metabolite accounts for more than 10% of plasma drug exposure. Biological Half-Life: The median half-life after oral administration is 10 to 12 days; the median half-life after subcutaneous administration is 8 to 12 weeks.

Hepatotoxicity
In a small, open-label clinical trial conducted before market launch, 10% of patients experienced elevated serum transaminases, with two cases (3%) exceeding five times the upper limit of normal. Both patients presented with jaundice. However, other causes of liver injury were identified in both cases: one attributable to alcoholic hepatitis, and the other to “reconstruction syndrome” resulting from the recovery of the immune response after successful HIV replication control. Both patients continued lenacapavir treatment and recovered successfully. Since lenacapavir’s approval and widespread use, no published cases of lenacapavir-related liver injury have been reported. One drawback of long-acting drugs like lenacapavir is that treatment cannot be immediately discontinued if toxicity or intolerance occurs. Finally, in patients with a history of chronic hepatitis B or C, the recovery of the immune response following the addition of lenacapavir to an ineffective antiretroviral therapy regimen may lead to reconstruction syndrome and relapse of chronic viral hepatitis.
Probability Score: E (Unlikely to be the cause of liver injury with specific clinical manifestations).
Effects during pregnancy and lactation
◉ Overview of use during lactation
There is currently no information regarding the use of lenakapavir during lactation. Because the drug has a protein binding rate exceeding 98.5%, its concentration in breast milk is likely to be low. Achieving and maintaining viral suppression through antiretroviral therapy can reduce the risk of breast milk transmission to below 1%, but not zero. For HIV-infected individuals receiving antiretroviral therapy with a persistently low viral load below the detection limit, breastfeeding should be supported if they choose to do so. If viral load is not suppressed, pasteurized donor breast milk or formula is recommended.
◉ Effects on breastfed infants
No published information found as of the revision date.
◉ Effects on lactation and breast milk
No published information found as of the revision date.

---

Protein binding
In vitro studies have shown that lenakapavir binds to plasma proteins at a rate of approximately 99.8%.

[1]. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front Microbiol. 2019 Jun 20;10:1227.

[2]. Clinical targeting of HIV capsid protein with a long-acting small molecule

[3]. Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model. J Clin Invest. 2023 Aug 15; 133(16): e167818.

Pharmacodynamics
Lenacapavir is an antiviral drug with prolonged pharmacokinetic characteristics. Lenacapavir combats HIV-1 by inhibiting viral replication: it interferes with multiple key steps in the viral life cycle, including viral uptake, assembly, and release. In healthy volunteers, a single subcutaneous injection of ≥100 mg resulted in plasma concentrations exceeding the 95% effective concentration (EC95) and maintained for ≥12 weeks, while an injection of ≥300 mg resulted in plasma concentrations exceeding EC95 and maintained for ≥24 weeks. In treatment-naïve HIV-1 infected individuals, a single subcutaneous injection of 20–450 mg resulted in a mean maximum log10 shift of plasma HIV-1 RNA of 1.35–2.20 on day 9 post-injection. Lenacapavir is a prescription drug and has been approved by the U.S. Food and Drug Administration (FDA). It is approved under two different brand names for the following uses:
Lenacapavir oral tablets and injections (brand name: Sunlenca)
For the treatment of HIV-infected adults who have not responded to other HIV medications and meet specific criteria determined by a healthcare provider. Lenacapavir for HIV treatment must be used in combination with other HIV medications.
Lenacapavir oral tablets and injections (brand name: Yeztugo)
For HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection in adults and adolescents who weigh at least 35 kg (77 lbs), have a negative HIV test, and are at risk of sexually transmitted HIV infection. When used for PrEP, lenakacapavir should always be used in conjunction with safe sex practices (such as condom use) to reduce the risk of contracting other sexually transmitted infections.
Despite the availability of several successful therapies, HIV/AIDS remains a concerning area, primarily due to the emergence of multidrug resistance and difficulties in adhering to treatment regimens. Lenacapavir is a first-in-class capsid inhibitor that achieves picomolar-level HIV-1 inhibition with in vitro monotherapy. It exhibits virtually no cross-resistance with existing antiretroviral drugs and has a longer pharmacokinetic profile when administered subcutaneously. On August 22, 2022, the European Commission approved lenacapavir for the first time for the treatment of multidrug-resistant HIV infection in adults. On December 22 of the same year, the U.S. Food and Drug Administration (FDA) also approved lenacapavir for marketing. Lenacapavir is a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor. Its mechanism of action includes inhibition of the HIV capsid, cytochrome P450 3A, P-glycoprotein, and breast cancer resistance protein. Lenacapavir is a human immunodeficiency virus (HIV) capsid inhibitor, often used in combination with other antiretroviral drugs to treat patients with multidrug-resistant HIV infection. Lenacapavir has a long-acting effect and is available in oral tablets and subcutaneous injection solutions. It has a long half-life and can be administered once every 26 weeks. Serum transaminase levels are transiently and usually mildly elevated during Lenacapavir treatment, but the incidence is low and has not been found to be associated with clinically significant cases of acute liver injury. LENACAPAVIR is a small molecule drug, with clinical trials up to Phase IV (covering all indications), first approved in 2022, and currently has 3 approved indications and 2 investigational indications. Mechanism of Action: HIV-1 utilizes multiple host factors during its replication cycle, including host cell entry, nuclear integration, replication, and viral particle assembly. After the viral capsid fuses with the host cell membrane, it is released into the host cytoplasm. The capsid consists of approximately 250 hexamers and 12 pentamers, each composed of a capsid protein monomer (CA). Each CA monomer has an N-terminal domain and a C-terminal domain (NTD/CTD), providing an interaction surface for host cell mechanisms. Several important protein-protein interaction interfaces exist between CA monomers in the assembled multimers; the binding constants of these proteins in the assembled multimers are significantly lower than those in individual capsid monomers. To facilitate HIV-1 genome integration, the capsid must cross the nuclear membrane, a process accomplished using the nuclear pore complex (NPC). Two host proteins confirmed to be crucial for capsid entry into the nucleus are cleavage and polyadenylation-specific factor subunit 6 (CPSF6) and nuclear porein 153 (Nup153, a protein located on the nucleoplasmic side of the NPC complex), which bind directly to the capsid. In the multimeric CA assembly, both proteins bind to the same phenylalanine-glycine binding pocket between the N-terminal domain (NTD) and C-terminal domain (CTD) of adjacent CA monomers. Lenacapaver contains a difluorobenzyl ring that occupies the same binding pocket as CPSF6/Nup153, overlapping in an overlapping structure with the benzyl groups of F321 in CPSF6 and F1417 in Nup153. The crystal structure of lenacapavir bound to CA hexamers shows that each hexamer binds six lenacapavir molecules, forming extensive hydrophobic interactions, two cation-π interactions, and seven hydrogen bonds, contacting approximately 2000 Ų of the buried protein surface area. Therefore, the strong binding of lenacapavir competitively interferes with the interaction between the capsid and CPSF6 and Nup153. In vitro experiments showed that lenacapavir inhibited HIV-1 replication in various cell lines with EC50 values of approximately 12–314 pM, with better inhibition of early replication steps than late replication steps. At very low concentrations (0.5 nM), lenacapavir inhibited viral nuclear transport; at higher concentrations (5–50 nM), it also inhibited viral DNA synthesis and reverse transcription. Since CPSF6 and Nup153 are crucial for viral nuclear transport, the binding of lenacapavir likely inhibits these interactions, thereby blocking capsid nuclear transport. The mechanism of action of lenacapavir may extend beyond blocking interactions with host cytokines. Lenacapavir enhances the rate and extent of CA assembly, significantly prolonging the lifetime of assembled CA structures, even at high salt concentrations, and alters the morphology of the assembled capsid. Its stable concentration is approximately 1:1, very close to the observed binding stoichiometry of isolated CA hexamers. Further analysis indicates that lenacapavir binding alters the interactions within and between hexamers, thereby changing the structure and stability of the final assembly. Serial passages of HIV-1 virus in escalating lenacapavir solutions resulted in the emergence of the major resistance mutations Q67H and N74D, which remain sensitive to other antiretroviral drugs. Further passages yielded other mutations L56I, M66I, K70N, N74S, and T107N. All identified resistance mutations were located at the lenacapavir binding site, and all mutations except Q67H exhibited reduced in vitro replication capacity. Other studies have shown no resistance to lenakapavir in variants or naturally occurring polymorphisms associated with resistance to other antiretroviral agents, suggesting a very low likelihood of cross-resistance in combination therapy.

---

Drug Indications
Lenacapavir, in combination with other antiretroviral agents, is indicated for the treatment of adults with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection who have failed their current antiretroviral regimen due to resistance, intolerance, or safety concerns.
Sunlenca injection, in combination with other antiretroviral agents, is indicated for the treatment of adults with multidrug-resistant HIV-1 infection for whom a suppressive antiretroviral regimen cannot be constructed (see Sections 4.2 and 5.1). Sunlenca tablets, in combination with other antiretroviral agents, are indicated for the treatment of adult patients with multidrug-resistant HIV-1 infection for whom a suppressive antiretroviral regimen cannot be constructed, as an oral loading therapy prior to injection of long-acting lenakapavir (see Sections 4.2 and 5.1).
Yeytuo tablets, used in conjunction with safe sex practices, are for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection via sexual transmission in adults and adolescents (weighing at least 35 kg) at increased risk of HIV-1 infection: • Oral loading therapy • Oral bridging therapy (see Sections 4.2, 4.4, and 5.1)

---

Hepatotoxicity Overview
Lenacapapvir is a human immunodeficiency virus (HIV) capsid inhibitor used in combination with other antiretroviral drugs to treat patients with multidrug-resistant HIV infection. Lenapapvir has a long duration of action and is available in oral tablets and subcutaneous injection solutions. It has a long half-life and can be administered once every 26 weeks. The incidence of transient and usually mild elevations in serum transaminase levels during lenapapvir treatment is low, but has not been found to be associated with clinically significant cases of acute liver injury.

C39H32CLF10N7O5S2

968.2823

967.14

C, 48.38; H, 3.33; Cl, 3.66; F, 19.62; N, 10.13; O, 8.26; S, 6.62

2189684-44-2

2283356-18-1 (HCl); 2937414-47-4 (Lenacapavir pacfosacil); 2189684-44-2;2283356-12-5 (sodium);

133082658

White to light yellow solid powder

6.4

2

19

13

64

2040

3

CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C

BRYXUCLEHAUSDY-WEWMWRJBSA-N

InChI=1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1

N-((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

Lenacapavir; GS-6207; GS 6207; GS6207; GS 714207; GS-714207; GS714207; GS-CA-2; GS-CA2; GS-HIV;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~200 mg/mL (~206.55 mM)

Solubility in Formulation 1: ≥ 6.25 mg/mL (6.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly.

---

Solubility in Formulation 2: 2.5 mg/mL (2.58 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

 (Please use freshly prepared in vivo formulations for optimal results.)